drugset / Trial / NCT05368935

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

NCT05368935

Phase 1 Completed 77 enrolled Genfit
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with renal impairment and healthy adults.

Timeline

Start
2022-04-25
Primary completion
2022-09-04
Completion
2022-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified 500 mg Oral